Фармакологическое и клиническое изучение отечественного С1-эстеразного ингибитора при системной воспалительной реакции
Диссертация
Учитывая перспективы применения нового отечественного препарата С1-эстеразного ингибитора, полученного оригинальным способом, в клинической практике, требуется проведение полного спектра доклинического и клинического изучения безопасности и эффективности препарата у больных сепсисом. С1-ингибитор относится к иммунобиологическим препаратам, что определяет существенные отличия в фармакокинетике… Читать ещё >
Содержание
- Общая характеристика работы
- Актуальность
- Цель исследования
- Задачи исследования
- Научная новизна
- Практическая значимость
- Внедрение в практику
- Положения, выносимые на защиту
- Апробация работы
- Публикации
- Глава 1. Обзор литературы
- Глава 2. Материалы и методы
- Глава 3. Характеристика состояния системы комплемента в рамках системной воспалительной реакции
- Глава 4. Изучение фармакологической активности С1-эстеразного ингибитора в условиях экспериментального сепсиса
- Глава 5. Изучение безопасности С1-эстеразного ингибитора при введении лабораторным животным
- Глава 6. Фармакокинетический анализ С1-эстеразного ингибитора
- Глава 7. Фармакодинамический анализ
- Глава8. Изучение клинической эффективности применения С1-эстеразного ингибитора у больных сепсисом в составе комплексной терапии
- Глава 9. Оценка безопасности препарата С1-эстеразного ингибитора при внутривенном введении
- Глава 10. Обсуждение результатов собственных исследований
Список литературы
- Brun-Buisson, С. The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis / C. Brun-Buisson, F. Roudot-Thoraval, E. Girou // Intensive Care Med. 2003. — V. 29. — P. 1464^1471.
- Angus, D. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care/ D. C. Angus, W. T. Linde-Zwirble, J. Lidicker // Crit. Care Med. 2001. — V. 29. — P. 1303−1310.
- Martin GS, Mannino DM, Eaton et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003 348: 1546−1554.
- Brun-Buisson, C. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units / C. Brun-Buisson, P. Meshaka, P. Pinton // Intensive Care Med. 2004. — V. 30. — P. 580−588.
- Quartin, A. Magnitude and duration of the effect of sepsis on survival / A. Quartin, R. M. H. Schein, D. H. Kett // JAMA. 1997. — V. 277. — P.1058−1063.
- Alberti, C. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients/ C. Alberti, C. Brun-Buisson, S. V. Goodman // Am. J. Resp. Crit. Care Med. 2003. — V. 168. — P. 77−84.
- Ashare, A. Anti-inflammatory response is associated with mortality and severity of infection in sepsis / A. Ashare, L. S. Powers, N. S. Butler //Am. J. Physiol. -2005. -V. 288. P. 633−640.
- Vincent, J. Sepsis Occurrence in Acutely 111 Patients Investigators (2006) Sepsis in European intensive care units: results of the SOAP study / J. L. Vincent, Y. Sakr, C. L. Sprung // Crit. Care Med. 2006. — V. 34. — P. 344^-353.
- Bone RC: Pulmonary and Critical Care Medicine, ed. Mosby Year Book Inc. 1998
- Morrison DC, Danner RL, Dinarello CA, et al: Bacterial endotoxins and pathogenesis of gram-negative infections: Current status and future direction. J Endotoxin Res 1994- 1:71−83
- Rietschel, E. Т., Т. Kirikae, F. U. Schade, et al. Bacterial endotoxin-molecular relationships of structure to activity and function. 1994- FASEB J. 8:217−225.
- Suffredini AF, Gromm RE, Parker MM, et al: The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989- 321:280 287
- Ishiguro, E. E., D. Vanderwel, and W. Kusser. Control of lipopoly-saccharide biosynthesis and release by Escherichia coli and Salmonella typhimurium. J. Bacterid. 1986 168:328−333.
- Hoekstra, D., J. W. Van Der Laan, L. De Leij, and B. Witholt. Release of outer membrane fragments from normally growing Escherichia coli. Biochim. Biophys. Acta 1976 455:889−899.
- Fenton MJ, Golenbock DT: LPS-binding proteins and receptors. J Leukoc Biol 64:25−32, 1998
- Appelmelk BJ, An YQ, Thijs BG, et al: Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand. Infect Immun 62:3564−3567, 1994
- Wright, S. D., R. A. Ramos, P. S. Tobias, R. J. Ulevitch, and J. C. Mathison. CD 14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. //Science 1990 249:1431−1433.
- O’Neill LA, Dinarello CA: The ИЛ-1 receptor/toll-like receptor superfamRJIy: crucial receptors for inflammation and host defense.//Immunol Today 2000, 21:206−209.
- Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, Janeway CA Jr: MyD88 is an adapter protein in the hToll/il-1 receptor family signaling pathways. Mol Cell 1998,2:253−258.
- Timmerman CP, Mattsson E, Martinez-Martinez L, et al: Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993- 61: 4167−4172
- Dziarski R: Cell-bound albumin is the 70-kDa peptidoglycan-, lipopolysaccharide-, and lipoteichoic acid-binding protein on lymphocytes and macrophages. //J Biol Chem 269:20 431−20 436, 1994
- Weidemann B, Brade H, Rietschl ET, et al: Soluble peptidoglycan-induced monokine production can be blocked by anti-CD 14 monoclonal antibodies and by lipid A partial structures. //Intensive Care Medicine 20(suppl 1):S10, 1994
- Michael A. Flierl, Daniel Rittirsch, Brian A. Nadeau, et al. Functions of the complement components C3 and C5 during sepsis. FASEB J, Oct 2008- 22: 3483 3490.
- MR Haeney. The role of the complement cascade in sepsis J. Antimicrob. Chemother., Jan 1998- 41: 41 46.
- Peter A. Ward. Role of the complement in experimental sepsis J. Leukoc. Biol., Mar 2008- 83: 467 470.32Hack CE, Voerman HJ, Eisele В, et al. CI esterase inhibitor substitution in sepsis.// Lancet.- 1992.- 339.- P. 378.
- Stevens JH, O’Hanley P, Shapiro JM, et al: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986 — 77: 1818−1826
- Fischer MB, Prodeus AP, Nicholson-Weller A, et al: Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by CI inhibitor replacement. J Immunol 1997 — 159: 976−982
- Cavaillon JM, Fitting С, Haeffner-Cavaillon N: Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990 — 20: 253−257
- LeGall JR, Klar J, Lemeshow S, et al: The logistic organ dysfunction system. JAMA 1996 — 276: 802−810
- Woo P, Lachmann PJL, Harrison RA and Amos N (1985) Simultaneous turnover of normal and dysfunctional CI inhibitor as a probe of in vivo activation of CI and contact activatable proteases. Clin Exp Immunol 61:1−8.
- Zahedi K, Prada AE, Prada JA and Davis AEr (1997b) Characterization of the INF-gamma-responsive element in the 59 flanking region of the CI-Inhibitor gene. J Immunol 159:6091−6096.
- Heda GD, Kehoe KJ, Mahdi F and Schmaier AH (1996) Phosphatase 2A participates in Interferon-g's induced upregulation of CI inhibitor mRNA expression. Blood 87:2831−2838.
- Schmidt B, Gyapay G, Valay M and Fust G (1991) Human recombinant macrophage colony-stimulating factor (M-CSF) increases CI-esterase inhibitor (C1INH) synthesis by human monocytes. Immunology 74:677−679.
- Lappin DF, Guc D, НИЛ1 A, McShane T and Whaley К (1992) Effect of interferongamma on complement gene expression in different cell types. Biochem J 281:437−442.
- Complement activation during sepsis in humans. H Schreiber, D Rittirsch, M Flierl, et al. Adv Exp Med Biol, Jan 2006- 586: 21 726.
- Weiss SJ (1989) Tissue destruction by neutrophHJIs. N Engl J Med 320:365 376.
- Ляшенко A.A. Уваров В. Ю. Цитокины и факторы роста: вопросы классификации. Доказательная медицина и молекулярная терапия в клинике внутренних болезней. Диалог-МГУ. (1999)
- Janeway, С. A., Jr. 2001. Appendix III, p. 677−679. In С. A. Janeway Jr., P. Travers, M. Walport, and M. J. Shlomchick (ed.), Immunobiology, 5th ed. Garland Publishing, New York, N.Y.
- Abraham E: Physiologic stress and cellular ischemia: Relationship to immunosuppression and susceptibility to infection. //Crit Care Med 1991- 19:613 618
- Browder W, WHJIliams D, Pretus H, et al: Beneficial effect of enhanced macrophage function in the trauma patient. Ann Surg- 211:605−612 (1990)
- Wakefield CH, Carey PD, Foulds S, et al: Changes in major histocompatibility complex class II expression in monocytes and T cells of patients developing infection after surgery. Br J Surg- 80:205−209 (1993)
- Bone RC: Sir Isaac Newton, sepsis, SIRS, CARS. Crit Care Med 24:1125−281 996)
- Murata A et al.: Cytokine imbalance in critically ИЛ1 patients: SIRS and CARS. Nippon Geka Gakkai Zasshi 100(7):414−8 (1999)
- Docke WD et al.: Monocytes deactivation in septic patients. Nat Med 3:678−811 997)
- Dendorfer U, Oettgen P, Libermann ТА: Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol 14: 4443−4454, 1994
- Papanicolaou DA, WRJIder RL, Manolagas SC, et al. The pathophysiologic roles of interleukin-6 in human disease. NIH conference. Ann Intern Med 1998−128:127−37.
- Fattori E, Cappelleti M et al. Defective inflammatory respomse in ИЛ6 deficient mice. J Exp Med 1994- 180:1243−50
- Igonin AA, Armstrong VW, Shipkova M, Kukes V, Oellerich M. The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia. Clin Chem Lab Med 2000- 38(11): 1125−1128
- Damas P, Canivet JL, DeGroote D, et al. Sepsis and serum cytokine concentrations. Crit Care Med. 1997−25:405−412
- Monton С et al. Cytokine expression in severe pneumonia: A bronchoalveolar lavage study Crit Care Med 1999- Vol.27, P. 1745−1753
- Dehoux MS, Boutten A, Ostinelli J, et al: Compartmentalized cytokine production within the human lung in unHJIateral pneumonia. Am J Respir Crit Care Med 1994- 150:710−716
- Monton С et al. Cytokine expression in severe pneumonia: A bronchoalveolar lavage study //Crit Care Med 1999- Vol.27, P.1745−1753
- Puren AJ, Feldman C, Savage N, et al: Patterns of cytokine expression in community acquired pneumonia. Chest 1995- 107: 1342−1349
- Ortqvist A, Hedlund J, Wretlind B, et al. Diagnostic and prognostic value of interleukin-6 and C-reactive protein in community acquired pneumonia. Scand J Infect Dis 1995- 27:457−462
- Meyer ТА, Wang J, Tiao GM, et al. Sepsis and endotoxemia stimulate interleukin-6 production. Surgery 1995−118:336−42
- Ertel W, Kremer JP et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 1995 85 (5): 1341−47
- Cohen, J. Diagnosis of infection in sepsis: An evidence-based review / J. Cohen, C. Brun-Buisson // Crit. Care Med. 2004. — V. 32, N. 11 (Suppl.l 1). -P. 466−494.
- Белобородова, Н. Диагностическая ценность некоторых маркеров инфекции в раннем послеоперационном периоде у кардиохирургичексих больных/ Н. В. Белобородова, Д. А. Попов // Анестизиология и реаниматология. 2005. — № 3. — С. 45−49.
- Reinhart, К. Markers for sepsis diagnosis: what is useful? / K. Reinhart, M. Meisner, F. M. Brunkhorst // Crit .Care Clin. 2006. — V. 22. — P. 503−519.
- Uzzan, B. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis / B. Uzzan, R. Cohen, P. Nicolas // Crit. Care Med. 2006. — V. 34. — P. 1996−2003.
- Christ-Crain, M. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial / M. Christ-Crain, D. Stolz, R. Bingisser // Am. J. Respir. Crit. Care Med. 2006. -V. 174. — P. 84−93.
- Novotny, A. Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis / A. Novotny Alexander, K. Emmanuel, E. Matevossian // The American Journal of Surgery. 2007. — V. 194. — P. 35−39.
- Lopez Sastre JB, Solis DP, Serradila VR et al. Evaluation of procalcitonin for diagnosis of neonatal sepsis of vertical transmission. BMC Pediatr.2007 Feb 26- 79
- Н.В.Белобородова, Д. А. Попов. Тест на прокальцитонин: алгоритмы применения и новые возможности. Пособие для врачей.М., 2008, 74С.
- Boussekey N., Leroy О, Alfandari S et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006−32(3):469−472.
- Casey, L. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome / L. C. Casey, R. A. Balk, R. C. Bone // Ann. Intern. Med. 1993. V. 119. — P. 771−778.
- Boeken U, Feindt P, Petzold T et al. Diagnostic value of procalcitonin: the influence of cardiopulmonary bypass, aprotinin, SIRS and sepsis. Thorac Cardiovasc Surg. 1998 Dec- 46 (6):348−51.
- Rivers, E. The influence of early hemodynamic optimization on biomarker patterns of severe sepsis and septic shock / E. P. Rivers, J. A. Kruse, G. Jacobsen // Crit. Care Med. 2007. — V. 35, № 9. — P. 2016 — 2024.
- Bernard, G. Efficacy and safety of recombinant human activated protein С for severe sepsis / G. R. Bernard, J. L. Vincent, P. F. Laterre// N. Engl. J. Med. 2001.- V. 344. P. 699−709.
- Vincent, J. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial / J. L. Vincent, D. C. Angus, A. Artigas // Crit. Care Med. 2003.- V.31. -P.834−840.
- Dellinger, R. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock/ R. P. Dellinger, J. M. Carlet, H. Masur// Crit. Care Med. -2004. V. 32, № 3. — P. 858−873.
- Abraham, E. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death / E. Abraham, P.F. Laterre, R. Garg //N. Engl. J. Med. 2005. -V.353.-P. 1332−1341.
- Ely, E. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis / E. W. Ely, P. F. Laterre, D. C. Angus // Crit. Care Med. -2003. V. 31. P. 12−19.
- Warren, B. Caring for the critically ill patient: high-dose antithrombin III in severe sepsis- a randomized controlled trial / B. L. Warren, A. Eid, P. Singer // JAMA. 2001.-V. 286.-P. 1869−1878.
- Wiedermann, С. High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: Efficacy and safety / C. J. Wiedermann, J. N. Hoffmann, M. Juers // Crit. Care Med. 2006. — V. 34, № 2. — P. 285 — 292.
- D. Annane, G. Umberto Meduri, and P. Marik Critical illness-related corticosteroid insufficiency and community-acquired pneumonia: back to the future!
- Eur. Respir. J., Jun2008- 31: 1150 1152.
- G Colin and D Annane. Corticosteroids and human recombinant activated protein С for septic shock. Clin Chest Med, Dec 2008- 29(4): 705−12.
- Dellinger, R. Surviving Sepsis Campaign: international guidelines formanagement of severe sepsis and septic shock:2008 / R. P. Dellinger, M.M. Levy, J. M. Carlet // Crit. Care Med. 2008. — V. 36, № 1. — P. 296 — 327.
- JC Schefold, S von Haehling, M Corsepius, et al. A novel selective extracorporeal intervention in sepsis: immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5a. Shock, Oct 2007- 28(4): 418−25.
- Bhole D., Stahl G. Therapeutic potential of targeting the complement cascade in critical care medicine. Critical Care Medicine Vol. 31, N 1, 2003.
- Czermak BJ, Sarma V, Pierson CL et al. Protective effects of C5a blockade in sepsis. Nat Med, Jul 1999- 5(7): 788−92.
- Caliezi С, Wuillemin WA, Zeerleder S, et al: CI-esterase inhibitor: An antiinflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000 — 52: 91—112
- Hack CE, OgMJIvie AC, Eisele В, et al: CI inhibitor substitution therapy in septic shock and in vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993 — 19: 19−28
- Stevens JH, O’Hanley P, Shapiro JM, et al: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986 — 77: 1818−1826
- P. Jansen, B. Eisele, I. de Jong, A. Changet al. Effect of CI Inhibitor on Inflammatory and Physiologic Response Patterns in Primates Suffering from Lethal Septic Shock The Journal of Immunology, 1998, 160: 475−484.
- Stevens JH, O’Hanley P, Shapiro JM, et al: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986 — 77: 1818−1826
- Zwijnenburg P., van der Poll Т., Florquin S. CI Inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice. The Journal of Infectious Diseases 2007- 106:115−23
- Stevens JH, O’Hanley P, Shapiro JM, et al: Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates. J Clin Invest 1986 — 77: ¦ 1818−1826
- Pharmacorinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Edited by B. Meibohm//2006 WilEY-VCH Veglag GmbH & Co. KGA, Weinheim, pp. 6, 28−30
- Molineux G: Peglication: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy. (2003) 23(Pt 2): 3S-8S.
- Findalay JWA, Das I: Validation of immunoassays for macromolecules from biotechnology. J. Clin. Ligand Assay (1998) 21:249−253
- Hartman C, Smeyers-Verbeke J, Massart DL, et all.: Validation of bioanalytical chromatographic metods. J. Pharm. Biomed. Annal. (1998) 17:193 218
- Guidelines for industry on bioanalytical method validation — A revisit with a decade of progress. Pharm. Res. (2000) 17:1551−1557.
- Сергиенко, В. Прикладная фармакокинетика: основные положения и клиническое применение./ В. И. Сергиенко, Р. Джелифф, И. Б. Бондарева. -М.: Издательство РАМН, 2003 г. 252с.
- Мирошниченко, И. Основы фармакокинетики./ И. И. Мирошниченко. -М.: ГЭОТАР-МЕД, 2002.-192с.
- Соловьев, В. Фармакокинетика. / В. Н. Соловьев, А. А. Фирсов, В. А. Филов. М. Медицина, 1980. — 494с.
- Холодов, JI. Клиническая фармакокинетика. / JI. Е. Холодов, В. П. Яковлев. -М.: Медицина, 1985. 464с.
- Пиотровский, В. Метод статистических моментов и внемодельные характеристики распределения и элиминации лекарственных средств / В. К. Пиотровский //Хим.-фарм. Журн. -1984.-Т. 18, № 7. С. 845−849.
- Белоусов Ю.Б. Руководство по фармакокинетике., М., 2006.
- Tang, L. Pharmacokinetic aspects of biotechnology products / L. Tang, A. M. Persky, G. Hochhaus // J. Pharm. Sci. 2004. — V. 93. P. 2184−2204.
- Pharmacorinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development. Edited by B. Meibohm//2006 WILEY-VCH Veglag GmbH & Co. KGA, Weinheim, p.3
- Colburn, W. 1991. Peptid, peptoid, and protein pharmacokinetics/pharmacodynamics. In: P. Garzone, W. Colburn, and M.
- Mokotoff (Eds.), Peptid, peptoid, and protein. Harvey Whitney Books Cincinnaty, OH, pp. 94−115
- Toon, S. The relevance of pharmacokinetics in the development of biotechnology products / S. Toon // Eur. J. Drug Metab. Pharmacokinet. — 1996. -V.21.-P. 93−103
- Mohler, M. Altered pharmacokinetics of recombinant human deoxyribonuclease in rats due to the presense of binding protein / M. Mohler, J. Cook, D. Lewis//Drug Metab. Dispos. 1993. — V.21. — P. 71−75.
- Tan, A. Atrial natriuretic peptid. An overview of clinical pharmacology and pharmacokinetics / A. C. Tan, T. Russel, T. Thien // Clin. Pharmacokinet. 1993. — V. 24. — P. 28−45.
- Stahl GL, Reenstra WR, Frendi G. Complement-mediated loss of endothelium relaxation of porcine coronary arteries: role of the terminal membrane attack complex. Circ Res 1995, 76:575−583
- Piscitelli, S. Pharmacokinetic studies with recombinant cytokines. Scientific issues and practical considerations / S. C. Piscitelli, W.D. Figg, W.P. Petros // Clin. Pharmacokinet. 1997. — V. 23. — P. 406 — 414.
- Leid, R. Cleavage and inactivation of human CI inhibitor by the human leukocyte proteinase, proteinase 3 / R. W. Leid, B.E.P.B. Ballieux, I. Van der Heijden // Eur. J. Immunol. 1993. — V. 23. — P. 2939−2944.
- Wallace, E. Degradation of Cl-inhibitor by plasmin: Implications for the control of inflammatory process / E. M. Wallace, S. J. Perkins, R. B. Sim // Mol. Med. 1997. -V. 3. — P. 385−396
- Stephen J. Wolf, Zachary D. Tebb, Richard L. Byyny, et al. Clinical Effectiveness and Early Goal-Directed Therapy for Severe Sepsis and Septic Shock Chest, Feb 2008- 133: 584 585.
- Smedsrod, В. Clearance of tissue plasminogen activator by mannose and galactose receptors in the liver / B. Smedsrod, M. Einarsson // Thromb. Haemost.- 1990. V. 63.-P. 60−66.
- Schellekens H. Bioequivalence and the immunogenisity of biopharmaceuticals. Nature Reviews. Drug Dis 2002- 1:457−62.
- Schellekens, H. Factors influencing the imunogenecity of therapeutic proteins / H. Schellekens //Nephrol. Dial. Transplant. 2005. — V. 20, Suppl. 6. — P. 3−9.
- Martin, G. The epidemiology of sepsis in the United States from 1979 through 2000 / G. S. Martin, D. M. Mannino, S. Eaton // N. Engl. J. Med. 2003. — V. 348.1. P.1546−1554.
- M Quastel, R Harrison, M Cicardi, et al. Behavior in vivo of normal and dysfunctional CI inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest, Apr 1983- 71(4): 1041−6.
- P Woo, PJ Lachmann, RA Harrison, et al. Simultaneous turnover of normal and dysfunctional CI inhibitor as a probe of in vivo activation of CI and contact activatable proteases. Clin Exp Immunol, Jul 1985- 61(1): 1−8.
- В J de Smet, JP de Boer, J Agterberg, et al. Clearance of human native, proteinase-complexed, and proteolytically inactivated CI-inhibitor in rats. Blood, Jan 1993- 81: 56 61.
- Hack, CE, Ogilvie, AC, Eisele, B. CI inhibitor substitution therapy in septic shock and in vascular leak syndrome induced by high doses of interleukin-2. Intensive Care Med 1993- 19,19−28
- JE Gadek, SW Hosea, JA Gelfand, et al. Replacement therapy in hereditary angioedema: successful treatment of acuteepisodes of angioedema with partly purified CI inhibitor N. Engl. J. Med., Mar 1980- 302: 542 546.
- Diris J., Hermens W., Hemker P. et al. Pharmacokinetics of Cl-inhibitor protein in patients with acute myocardial infarction. Clin Pharmacol Ther 2002- 72:498−504.
- C. de Zwaan, A.H. Kleine, J.H.C. Diris, et al. Continuous 48-h Cl-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction.//Eur. Heart J., Nov 2002- 23: 1670 1677.
- VH Donaldson, RR Harrison. Complexes of Cl-inhibitor (Cl-INH) and hemostatic enzymes in normal plasma. Adv Exp Med Biol, Jan 1983- 156: 149−55.
- Inhibition of acid sialidase by inorganic sulfate. A Greffard, N Trabelsi, H Terzidis, J Bignon, MC Jaurand, and Y Pilatte Biochim Biophys Acta, Mar 1997- 1334(2−3): 140−8.
- D Liu, S Cai, X Gu, et al. CI Inhibitor Prevents Endotoxin Shock Via a Direct Interaction with Lipopolysaccharide. The Journal of Immunology, 2003, 171: 2594−2601.
- P. Jansen, B. Eisele, I. de Jong et. Effect of CI Inhibitor on Inflammatory and Physiologic Response Patterns in Primates Suffering from Lethal Septic Shock. //The Journal of Immunology, 1998, 160: 475−484.
- Руководство по экспериментальному (доклиническому) изучению новых фармакологических веществ. Под ред. Фисенко В. П., Арзамасцева Е. В., Бабаяна Э. А. и др. М. «Ремедиум», 2000.
- Marquez-Velasco R., R. Bojalil, A.Buelna. et al. Anti-tumor necrosis antibody fragments protect in murine polymicrobial sepsis: concentration and early intervention are fundamental to the outcome. //Inflamm.Res.2006−55:378−384.
- Abraham, E., A. Anzueto, G. Gutierrez et al. 1998. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock: NORASEPTII Study Group. //Lancet 351: 929−933.
- Dinarello, C. A. 2001. Anti-cytokine therapies in response to systemic infection. //J. Invest. Dermatol. Symp. Proc. 6: 244−250